The recommended dose of docetaxel.

Adverse events reported in the docetaxel/cisplatin and fluorouracil vs cisplatin and fluorouracil–alone abstract entity included severe (grades 3/4) neutropenia (76.3% vs 52.8%), alopecia (10.9% vs 0%), blood disorder (9.2% vs 13.8%), and pathological process (8.6% vs 7.7%). However, decreased rates of grades 3/4 symptom (0.6% vs 7.2%), vomiting (0.6% vs 5.0%), and stomatitis (4.0% vs 11.0%) were noted. Commonly observed events in the docetaxel unit vs cisplatin and fluorouracil–alone chemical group (any severity) included febrile neutropenia (5.2% vs 2.2%) and neutropenic transmission (13.9% vs 8.3%).
The recommended dose of docetaxel for this indicant is 75 mg/m2 as a 1-hour intravenous instillation, followed by 75 mg/m2 of nexium intravenously for 1 hour on day 1 of the wheel. This is followed by 750 mg/m2 of fluorouracil as a continuous intravenous dose for 5 days. The regimen is administered every 3 weeks for 4 cycles. Patients must be premedicated with antiemetics and receive appropriate hydration prior to and after the cisplatin instilment. All patients in the docetaxel set of the examination received condom antibiotics.